Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab plus mini-CHOP in patients over 80 with DLBCL
NCT01195714Phase 2Completed
- Sponsor
- LYSARC
- Start
- May 2010
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of ofatumumab in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Primary endpoint: Overall Survival at 2 years. Started May 2010; status: completed.
02
Drugs
ofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01195714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01195714.